Cell therapy for active systemic sclerosis with lung involvement
Treatments studied
Part of Skin clinical trials.
This study tests an experimental cell therapy that targets your own immune cells to treat systemic sclerosis (scleroderma) with lung involvement. It aims to see if this treatment works better than standard care in reducing disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of systemic sclerosis (scleroderma) based on standard criteria.
- You have a positive ANA test with a nucleolar pattern and/or anti-Scl-70 antibodies.
- You have interstitial lung disease (ILD) that affects at least 10% of your lungs on a CT scan.
- You also have at least one active feature like arthritis, muscle inflammation, heart inflammation, progressive skin disease, or elevated inflammatory markers.
- You have tried at least one immunomodulatory drug for 6 months or more, but it did not control your disease or you couldn't tolerate it.
- You do not need supplemental oxygen, do not have severe pulmonary hypertension, and have not smoked (including e-cigarettes) recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, modified to attack faulty cells that drive systemic sclerosis. It's for people with active disease who haven't improved with standard therapies.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
This early-stage trial tests an investigational cell therapy for people with systemic sclerosis (scleroderma). The treatment uses your own modified immune cells to try to calm the overactive immune system and slow the disease, with imaging to see where the cells go in your body.
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.